The Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for patients with locally advanced or ...

Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...

Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

Oct. 17, 2024 — Scientists developed a way of using artificial intelligence to check for skin cancer with the AI tool, which was trained on data from 53,601 skin lesions from 25,105 patients ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...

Erythromycin: This antibiotic is used for several types of infections, including skin and pneumonia.

The CAIRO5 trial confirmed the benefit of both two-drug chemotherapy regimens with bevacizumab instead of a three-drug ...

Nidlegy is a fusion protein commercialized by Philogen, with a leading Phase III program in Metastatic Melanoma.

all patients developing positive DTH reactions had a clinical response of complete or partial rejection of metastatic lesions. Patient 2, who did not develop a positive skin reaction after ...

Evidence of metastatic spread should routinely be sought when examining patients. For patients with lesions less than 1 mm thick, close followup with biannual physical and skin examination is ...